SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Praetorian Acquisition Corp. - Ordinary Shares - Class A

Investors are closely monitoring Praetorian Acquisition Corp. following its recent public debut as the market evaluates the potential for future merger and acquisition activity from the newly formed blank check company.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending as investors react to the recent appointment of a new CFO and continued speculation regarding a potential hyperscaler tenant for its data center campus. Community discourse remains divided, with supporters highlighting upcoming catalysts and infrastructure scale, while skeptics point to the lack of official contract announcements and concerns over the company's delivery timeline.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone is trending as investors weigh its aggressive pivot toward private credit and AI-driven infrastructure against lingering concerns regarding industry-wide redemption pressures and valuation risks in the real estate sector. The community is sharply divided, with some betting on a long-term turnaround fueled by record dry powder and strategic deployment, while others are closely monitoring potential liquidity constraints that could signal broader credit cycle risks.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade is currently seeing significant momentum as investors digest its latest quarterly results, which showcased accelerating revenue growth and improved margins that suggest its AI-driven model is gaining traction. The stock remains a focal point for the retail community, who are actively debating its valuation versus its disruptive potential, while some traders continue to monitor for short-squeeze opportunities driven by high short interest and institutional interest.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending as investors react to a 31.5% stake acquisition of Distributed Technologies Research, a move that has fueled intense community debate over potential dilution versus strategic expansion into AI-driven finance. Traders are also closely watching the ticker's high beta to Bitcoin, with many speculating on upcoming announcements at the company's investor day as they weigh the stock's long-term potential against past patterns of volatility.

Rydex Investments - Invesco CurrencyShares Canadian Dollar Trust

Invesco CurrencyShares Canadian Dollar Trust

The Canadian dollar is experiencing heightened volatility as investors weigh persistent trade-policy uncertainties and fluctuating crude oil prices against the Bank of Canada's cautious interest rate approach. The community is actively debating the potential for further easing, keeping a close watch on how shifting trade relations and economic data impact the currency's near-term trajectory.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors show strong conviction in its proprietary Alpha DaRT oncology platform, bolstered by recent Japanese marketing approval and upcoming trial milestones. The community is actively discussing the stock's robust cash position, the absence of dilution risk, and the belief that the company is significantly undervalued as it transitions into a commercial-stage player.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is experiencing significant market interest following a strong quarterly earnings report that featured a double beat on top and bottom-line expectations and raised forward-looking guidance. The community is actively discussing the stock's impressive post-earnings price surge, debating the sustainability of its robotic surgery market dominance against potential margin pressures from tariffs and broader sector volatility.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently facing downward pressure as investors pivot away from safe-haven assets due to rising inflation fears and supply-side concerns triggered by the ongoing conflict in the Middle East. The community is actively debating whether current bond valuations offer a defensive hedge or if the broader economic strain from elevated energy costs and fiscal uncertainty will drive yields significantly higher.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as investors weigh recent legal escalations against competitive rivals alongside ongoing anticipation for federal integration pilot program updates and potential defense contract awards. Community sentiment remains deeply divided, balancing concerns over high cash burn and development delays against optimism for the stock's long-term positioning in the electric aviation sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>According to a report, AIG’s competitor, Chubb, approached the firm with an informal offer to acquire it; however, both Chubb and AIG denied the reports.</li><li>Citi maintained its ‘Neutral’ rating on AIG and assigned an $85 price target.</li><li>Piper Sandler raised its price target on the stock to $95 from $88 and maintained an ‘Overweight’ rating.</li></ul>American International Group (<a href="https://stocktwits.com/symbol/AIG">AIG</a>) stock drew investor attention on Monday after Citi analysts noted that merging with another large insurer would not benefit AIG.According to TheFly, Citi analysts wrote in a research note that they expect American International Group (AIG) to continue acquiring more firms rather than being acquired. Citi believes integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction. The firm maintained a ‘Neutral’ rating on the shares, with an $85 price target.Earlier in the month, an Insurance Insider US <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.insuranceinsiderus.com/article/2fpahsm5la3on7eapsfsw/all-topics/m-a/chubb-made-informal-takeover-approach-for-aig?zephr_sso_ott=LTYHsi">report</a> indicated that Chubb had approached AIG with an informal acquisition offer. However, both firms have reportedly <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.insurancenews.com.au/international/aig-not-for-sale-amid-reports-of-rival-s-interest">denied</a> the same, according to Insurance News.&nbsp;In another note, Piper Sandler raised its price target on AIG to $95 from $88 and maintained an Overweight rating. The firm expects favorable weather to mean most insurers will report strong or even stronger-than-expected results, but pricing commentary will likely be more pessimistic.<h2 class="st-heading-2">Expansion Amidst Streamlining Operations</h2>AIG’s CEO, Peter Zaffino, has been streamlining its operations since taking the reins in 2021 by selling its global personal travel business, and continues to make acquisitions and investments to make AIG into a more capital-aligned company.AIG recently announced it will invest around $5 billion in specialty insurer Convex and asset manager Onex Corporation. As part of the deal, AIG acquired a 35% stake in Convex for $2.1 billion. It also said it will acquire a 9.9% ownership stake in asset manager Onex for about $646 million and will also invest up to $2 billion in its investment funds.AIG also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.everestglobal.com/news/news-details/2025/Everest-Announces-Agreement-to-Sell-Retail-Commercial-Insurance-Renewal-Rights-to-AIG/default.aspx">acquired</a> renewal rights to Everest Group’s global retail insurance portfolio for about $2 billion, which will allow AIG to grow its general insurance arm by incorporating Everest’s existing customers.<h2 class="st-heading-2">How Did Stoctwits Users React?</h2>Retail sentiment around AIG trended in “bearish” territory amid “high” message volumes.<figure class="image"><img style="aspect-ratio:633/74;" src="https://news.stocktwits-cdn.com/AIG_PNG_22be5e3e02.webp" alt="Retail sentiment around AIG trended in “bearish” territory amid “high” message volumes" width="633" height="74"></figure>Shares of AIG have surged over 10% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

The AIG (American International Group) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Does Citi Believe AIG Is More Likely To ‘Acquire’ Than Be Acquired?

Citi analysts believe integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction.

Equity

Citi analysts believe integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction.


Boston Scientific Corporation (BSX) said on Friday that it has entered into a definitive agreement to acquire privately held medical technology company Nalu Medical for an upfront cash payment of approximately $533 million for equity not currently owned by the company.Nalu is developing minimally invasive solutions for patients with chronic pain, and Boston Scientific has been a strategic investor in the company since 2017.The transaction is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-nalu-medical-inc-302587495.html">expected</a> to be completed in the first half of 2026, subject to the satisfaction of customary closing conditions. The transaction is not expected to impact Boston Scientific’s adjusted earnings per share (EPS) in 2026. However, the company expects it to be slightly accretive to adjusted EPS in 2027 and increasingly accretive thereafter.BSX shares traded down 1% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BSX">BSX stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The acquisition is intended to expand the neuromodulation offerings for people living with chronic pain, Boston Scientific said."Adding the highly differentiated Nalu Medical technology complements our existing therapies—including spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation—enabling us to deliver advanced pain relief options to a wider variety of patient populations," President Jim Cassidy said.Nalu is expected to generate sales of more than $60 million in 2025 and to deliver year-over-year growth of over 25% in 2026.BSX stock is up by 9% this year and by about 13% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-falls-below-105-000-pulling-mstr-stock-lower-xrp-and-solana-drop/ch6sexmR383">Bitcoin Falls Below $105,000, Pulling MSTR Lower – XRP And Solana Drop Amid Banking Jitters</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A general view of a Boston Scientific advertisement during a women's college lacrosse game between the Notre Dame Fighting Irish and the Boston College Eagles on March 16, 2024. (Photo by Erica Denhoff/Icon Sportswire via Getty Images)

Boston Scientific To Acquire Privately-Held Pain Solutions Developer Nalu Medical For About $533M

Nalu Medical is developing minimally invasive solutions for patients with chronic pain, and Boston Scientific has been a strategic investor in the company since 2017.

Three varieties of McCormick spices in plastic table shaker containers. Salt free all purpose, garlic and herb and Perfect Pinch salt free garlic and herb. Variety of prepared and mixed Seasonings to add to any food dish.

McCormick CEO Flags Rising Prices On Global Trade Pressures: ‘Expect To Offset Rising Commodity Costs And Tariffs As Much As We Can’

McCormick now expects annual adjusted profit to be between $3 and $3.05 per share, compared with its previous estimate of $3.03 to $3.08 per share.

Med-tech company Medtronic (MDT) announced on Tuesday that its board of directors has appointed industry veterans John Groetelaars and Bill Jellison as independent directors, effective immediately, after Elliott Investment Management added a substantial stake in the firm.The company also announced the formation of two special committees. Of this, one will be responsible for guiding the evaluation and execution of growth-accretive tuck-in mergers and acquisitions, organic research and development investments, and potential divestitures.The other committee will align governance with the company's initiatives to optimize operational performance, deliver margin expansion, and drive sustained earnings acceleration, the company said.CEO Geoff Martha will serve as Chair of both of the newly formed committees, and both the newly appointed directors will serve on one or both of the committees. Groetelaars and Jellison will further be nominated to stand for election to the board at Medtronic's 2025 annual general meeting of shareholders, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://news.medtronic.com/2025-08-19-Medtronic-announces-Board-appointments-and-shareholder-value-creation-initiatives-to-advance-strategic-priorities">said</a>.The company said that the move followed dialogue with Elliott Investment Management L.P., which is now one of the largest investors in the company. Elliott Partner Marc Steinberg stated that the decision to become one of the largest investors in Medtronic was driven by the conviction that the company is entering a new chapter of value creation.“We believe Medtronic's recent innovations in some of the medical technology sector's most attractive markets have positioned the company for an inflection in organic growth… Today's announcements – including the addition of new directors with deep medical technology experience and the formation of two focused Board committees – are the right steps towards realizing Medtronic's potential,” Steinberg said.The Wall Street Journal reported the board appointments earlier today. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MDT">MDT</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_7_52_05_AM_png_5d5cc8d38a.webp" alt="MDT's Sentiment Meter and Message Volume as of 7:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="627" height="62"><figcaption>MDT's Sentiment Meter and Message Volume as of 7:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the company’s long-term value looks solid, if it can maintain steady revenue growth and keep innovating in key product lines.<stembedurl>https://stocktwits.com/JasonInsightMarkets/message/625725317</stembedurl>On Tuesday, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://news.medtronic.com/2025-08-19-Medtronic-reports-first-quarter-fiscal-2026-financial-results">reported</a> earnings for the first quarter of fiscal year 2026 (FY26), which ended July 25, and raised its FY26 earnings guidance. For FY26, the company continues to expect organic revenue growth of approximately 5%. It also raised its FY26 diluted and adjusted earnings per share guidance to the new range of $5.60 to $5.66 versus the prior range of $5.50 to $5.60.For the first quarter, the firm reported revenue of $8.578 billion, exceeding a Wall Street estimate of $8.371 billion. The growth was spurred by growth across the company’s cardiovascular, neuroscience, medical surgical, and diabetes business portfolios.Adjusted and diluted earnings per share in the quarter came in at $1.26, above an estimated $1.23.MDT stock is up by 16% this year and by about 9% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-readying-new-blackwell-based-b30-a-chip-for-china-as-us-tensions-flare-report/chsgO5iRdg9">Nvidia Readying New Blackwell-Based B30A Chip For China As US Tensions Flare: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Medtronic logo is displayed on a smartphone screen in front of a stock chart showcasing Medtronic's financial performance. (Photo by Cheng Xin/Getty Images)

Medtronic Appoints New Directors After Elliott Becomes Major Investor: Company Hikes FY26 Guidance After Q1 Beat

Elliott Partner Marc Steinberg stated that the decision to become one of the largest investors in Medtronic was driven by the conviction that the company is entering a new chapter of value creation. 

Analysts are optimistic about Medtronic (MDT) after the Centers for Medicare and Medicaid Services (CMS) proposed to cover renal denervation for uncontrolled hypertension.CMS on Thursday posted its proposed decision memo, stating that it proposes to cover radiofrequency renal denervation and ultrasound renal denervation for uncontrolled hypertension. The agency is now seeking comments on its proposed decision, and a final decision is expected by October 8.Renal denervation (RDN) is a new technology that uses catheters placed into the renal (kidney) arteries to ablate, or destroy, the renal sympathetic nerves to reduce blood pressure. RDN is intended to complement medications and lifestyle changes in patients with uncontrolled hypertension.Hypertension can lead to serious problems such as heart attack and stroke, the agency noted.Medtronic, the medical technology provider, has an RDN system called Symplicity Spyral, which was granted FDA premarket approval in November 2023. The system disrupts the overactive sympathetic signaling between the kidneys and brain to reduce blood pressure.<a href="https://stocktwits.com/symbol/MDT">MDT shares </a>were trading 1% higher at the time of writing.&nbsp;Several analysts reacted to the news:<ul style="list-style-type:square;"><li>Stifel maintains a ‘Hold’ rating and $87 price target on Medtronic shares. The Centers for Medicare &amp; Medicaid Services' initial proposal for renal denervation reimbursement "seems positive," the firm noted.</li><li>JPMorgan, meanwhile, keeps a ‘Neutral’ rating on Medtronic. JPMorgan told investors in a research note that there is no arguing that a broad national coverage decision for renal denervation is a win for Medtronic. This will enable the company to begin targeting the potentially multi-billion-dollar opportunity once the final rule is released in October, according to the analyst. However, JPMorgan believes it will "take some time to get there" as the company will need to educate primary care physicians and general cardiologists.</li><li>BTIG analyst Ryan Zimmerman keeps a ‘Neutral’ rating on Medtronic. BTIG said that while the news was expected, it is still a win for Medtronic. BTIG believes the decision opens up Medtronic to a "massive" potential patient pool.</li></ul>&nbsp;On Stocktwits, retail sentiment around Medtronic stayed within ‘neutral’ territory over the past 24 hours while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_1_28_21_PM_png_9314bf702a.webp" alt="MDT's Sentiment Meter and Message Volume as of 1:30 p.m. ET on July 11, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>MDT's Sentiment Meter and Message Volume as of 1:30 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>MDT stock is up by nearly 13% this year and by over 15% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/cel-sci-to-sign-partnership-with-saudi-arabian-pharma-company-for-cancer-drug/ch8c1PLR5ZC">CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CMS’s Initial Proposal To Cover Renal Denervation A Win For Medtronic, Says Analysts

CMS is now seeking comments on its proposed decision, and a final decision is expected by October 8.

Health technology company Medtronic plc (MDT) on Tuesday announced the appointment of Chad Spooner as CFO of MiniMed.The appointment comes ahead of MiniMed’s separation from Medtronic as a standalone, public company. MDT shares are trading 1% higher at the time of writing.Medtronic announced its <a href="https://stocktwits.com/news-articles/markets/equity/medtronic-announes-split-of-diabetes-business/ch0ec0dRbYg">intent to split</a> its Diabetes business into a standalone company in May. The move, it said, will create a more focused Medtronic, with a more simplified portfolio including cardiovascular, neuroscience, and medical-surgical.The company also noted that the separation is expected to be accretive to Medtronic’s earnings and operating margin.<a href="https://stocktwits.com/symbol/MDT">Medtronic</a> expects the separation to be completed within 18 months of the initial announcement. The company is eyeing an initial public offering (IPO) and subsequent split-off.Que Dallara will be the CEO of the new diabetes company, named MiniMed, which is expected to have over 8,000 employees. Dallara is currently the President of Medtronic Diabetes.Spooner’s appointment will be effective July 14, and he will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives.He was most recently CFO at BIC, a publicly traded global consumer goods company. Dallara also held leadership roles across healthcare, consumer, and industrial sectors, including at Raffaela Apparel Group, Slingshot Health, and Tenex Capital Management.Medtronic’s diabetes portfolio reported revenue of $2.76 billion in fiscal year 2025 (FY25), marking a growth of 10.7% year-on-year (YoY) and representing 8% of Medtronic’s total revenue in the period.On Stocktwits, retail sentiment around Medtronic is trending in the ‘neutral’ territory over the past 24 hours, coupled with ‘high’ message volume.<figure class="image"><img style="aspect-ratio:1378/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_08_at_12_41_52_PM_png_5beb980fab.webp" alt="MDT's Sentiment Meter and Message Volume as of 12:40 p.m. ET on July 8, 2025 | Source: Stocktwits" width="1378" height="122"><figcaption>MDT's Sentiment Meter and Message Volume as of 12:40 p.m. ET on July 8, 2025 | Source: Stocktwits</figcaption></figure>MDT stock is up by 11% this year and by about 15% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-seeks-approval-for-higher-wegovy-dose-in-europe/chFvDEAR5Wj">Novo Nordisk Seeks Approval For Higher Wegovy Dose In Europe</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medtronic Names CFO For New Diabetes Company Ahead Of Intended Spin-Off

Chad Spooner’s appointment will be effective July 14, and he will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives.

XRLV
Invesco S&P 500 ex-Rate Sensitive Low Volatility ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XRLV News

XRLVInvesco S&P 500 ex-Rate Sensitive Low Volatility ETF